TherapeuticsMD (TXMD) Other Non-Current Assets (2010 - 2026)
TherapeuticsMD (TXMD) posted Other Non-Current Assets of $419000.0 for Q1 2026, down 5.63% on a QoQ basis from $444000.0 in Q4 2025, and up 98.58% year-over-year from $211000.0 in Q1 2025.
TherapeuticsMD (TXMD) Other Non-Current Assets (2010 - 2026) Analysis & Trends
TherapeuticsMD's Other Non-Current Assets history runs 17 years deep, the most recent figure standing at $419000.0 for Q1 2026.
- Quarterly Other Non-Current Assets rose 98.58% year-over-year to $419000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $419000.0 (up 98.58% YoY) and the FY2025 annual result came in at $444000.0, up 241.54% from the prior year.
- Other Non-Current Assets was $419000.0 for Q1 2026 at TherapeuticsMD, down from $444000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $470000.0 in Q3 2025 and bottomed at $58000.0 in Q1 2024.
- A 5-year average of $258470.6 and a median of $253000.0 in 2022 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets slumped 99.25% — and 2025, when it surged 710.34%.
- TherapeuticsMD's Other Non-Current Assets stood at $253000.0 in 2022, then soared by 35.97% to $344000.0 in 2023, then tumbled by 62.21% to $130000.0 in 2024, then surged by 241.54% to $444000.0 in 2025, then slipped by 5.63% to $419000.0 in 2026.
- Business Quant data shows TXMD's Other Non-Current Assets at $419000.0 in Q1 2026, $444000.0 in Q4 2025, and $470000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 49.22 Mn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 1.79 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 351.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 491.06 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 233.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.11 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 73.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 295.00 Mn |
| 10 | TherapeuticsMD | 280,159.99 | -8.14 Mn | - | 419,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 419,000.00 |
| Dec 31, 2025 | 444,000.00 |
| Sep 30, 2025 | 470,000.00 |
| Jun 30, 2025 | 428,000.00 |
| Mar 31, 2025 | 211,000.00 |
| Dec 31, 2024 | 130,000.00 |
| Sep 30, 2024 | 58,000.00 |
| Jun 30, 2024 | 58,000.00 |
| Mar 31, 2024 | 58,000.00 |
| Dec 31, 2023 | 344,000.00 |
| Sep 30, 2023 | 254,000.00 |
| Jun 30, 2023 | 254,000.00 |
| Mar 31, 2023 | 253,000.00 |
| Dec 31, 2022 | 253,000.00 |
| Sep 30, 2022 | 253,000.00 |
| Jun 30, 2022 | 254,000.00 |
| Mar 31, 2022 | 253,000.00 |
| Dec 31, 2021 | 33.55 Mn |
| Sep 30, 2021 | 253,000.00 |
| Jun 30, 2021 | 253,000.00 |